2007
DOI: 10.1016/j.jmmm.2006.11.192
|View full text |Cite
|
Sign up to set email alerts
|

Magnetic nanoparticles for local drug delivery using magnetic implants

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
37
0

Year Published

2008
2008
2024
2024

Publication Types

Select...
5
1
1

Relationship

0
7

Authors

Journals

citations
Cited by 74 publications
(38 citation statements)
references
References 20 publications
(19 reference statements)
1
37
0
Order By: Relevance
“…Except for some experiments in which the direct intratumor or transdermic injection of the magnetic particles has been tested,12, 73 most examples of use of these particles refer to parenteral (intravenous or intraarteral) injection. This means that the colloids will come into contact with a liquid of slightly basic pH (7.4) and with a relatively high ionic strength (130–150 meq/L).…”
Section: Surface Charge and Wettability Role And Experimental Determmentioning
confidence: 99%
See 1 more Smart Citation
“…Except for some experiments in which the direct intratumor or transdermic injection of the magnetic particles has been tested,12, 73 most examples of use of these particles refer to parenteral (intravenous or intraarteral) injection. This means that the colloids will come into contact with a liquid of slightly basic pH (7.4) and with a relatively high ionic strength (130–150 meq/L).…”
Section: Surface Charge and Wettability Role And Experimental Determmentioning
confidence: 99%
“…However, at least an order of magnitude evaluation can be done in a relatively easy way. Since the field is typically applied externally (see, however, Ref 73. for the case of a magnet inserted directly in the receptor organ), the gradient will rapidly decrease upon passing through the nonmagnetic tissues and reaching the tumor.…”
Section: Magnetic Guidance and Particle Biodistributionmentioning
confidence: 99%
“…To our knowledge, the blood biocompatibility of these products has not been established to date. 16 Some studies have evaluated the compatibility of nanoparticles with the blood coagulation system 17 in vivo in rats 18 and rabbits, 19 while most of the authors have carried out only in vitro tests. 10 We have carried out an extensive in vitro biocompatibility study of our bioferrofluids with blood including coagulation studies, hemolysis and quantification of leukocytes, erythrocytes and platelets, to rule out immediate cytotoxicity of nanoparticles or contact spontaneous platelet aggregation.…”
Section: Introductionmentioning
confidence: 99%
“…This feature has been utilized in bioengineering and biomedicine, especially as contrast agents for magnetic resonance imaging (MRI) and as carriers for drug-targeted delivery [1][2][3][4][5][6][7][8]. Indeed, the magnetic nanoparticles were generally coated with protective shells as magnetic polymer microparticles because of their minimum toxicity and immunological response, and the polymeric shells would also provide favorable functional groups and protect from particle aggregation [9][10][11][12][13][14].…”
Section: Introductionmentioning
confidence: 99%
“…Conventional methods for introducing magnetic nanoparticles into polymer microparticles can be divided into three classes [15,16]: (1) coating the magnetic nanoparticles directly by polymer, such as emulsion-solvent evaporation [17]; (2) filling the magnetic nanoparticles into porous presynthesized polymer microparticles, such as swelling [18]; (3) dispersing the magnetic nanoparticles during the synthesis of polymer microparticles, such as suspension [19], dispersion [20], emulsion [21] and mini/micro-emulsion [22,23] polymerization in the presence of magnetic nanoparticles.…”
Section: Introductionmentioning
confidence: 99%